Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

5(42%)

Results Posted

50%(1 trials)

Terminated

1(8%)

Phase Distribution

Ph phase_1

17%

Ph phase_2

58%

Ph phase_4

Ph phase_3

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution12 total trials

Phase 1Safety & dosage

2(16.7%)

Phase 2Efficacy & side effects

7(58.3%)

Phase 3Large-scale testing

2(16.7%)

Phase 4Post-market surveillance

1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(9)

Completed(2)

Terminated(1)

Detailed Status

Recruiting4

Not yet recruiting4

Completed2

Active, not recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 4

Trials by Phase

Phase 12 (16.7%)

Phase 27 (58.3%)

Phase 32 (16.7%)

Phase 41 (8.3%)

Trials by Status

recruiting433%

not_yet_recruiting433%

active_not_recruiting18%

completed217%

terminated18%

Recent Activity

5 active trials

Showing 5 of 12

recruitingphase_3

Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

NCT07498907

not_yet_recruitingphase_2

HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.

NCT07528768

recruitingphase_4

A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer

NCT07619235

not_yet_recruitingphase_2

Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma

NCT07774234

recruitingphase_1

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766

View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials

NCT07498907Phase 3

Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

Recruiting

NCT07528768Phase 2

HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.

Not Yet Recruiting

NCT07619235Phase 4

A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer

Recruiting

NCT07774234Phase 2

Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma

Not Yet Recruiting

NCT04198766Phase 1

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Recruiting

NCT05141149Phase 1

First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer

Active Not Recruiting

NCT07578337Phase 2

A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.

Not Yet Recruiting

NCT07451652Phase 2

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

Recruiting

NCT07411144Phase 2

Gemcitabine as Maintenance Treatment for Diffuse Pleural Mesothelioma

Completed

NCT07272109Phase 3

Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes

Not Yet Recruiting

NCT04602078Phase 2

Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma